An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Trial Profile

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Desoximetasone (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 26 Jan 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2018.
    • 26 Jan 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Nov 2018.
    • 16 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top